FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067832306> ?p ?o ?g. }

• W2067832306 endingPage "292" @default.
• W2067832306 startingPage "284" @default.
• W2067832306 abstract "There is no available targeted therapy for triple-negative or its more aggressive subtype, basal-like breast cancer. Multiple therapeutic strategies based on translational knowledge have not improved the treatment options for triple negative patients. As understanding of molecular pathways that drive tumor development is rapidly increasing, it is imperative to adapt our treatment strategies to perturbations in molecular pathways driving the malignant process. Basal-like breast cancers over-express EGFR (without mutations or EGFR gene amplifications) and have p53 mutations. While EGFR drives the malignant behavior in triple negative breast cancer (TNBC), anti-EGFR therapies have fallen short of the expected results in clinical trials. Here we bring evidence that the less than optimal results of the anti-EGFR therapies may be explained in part by the increased potency of the EGFR signaling due to increased endosomal recycling. The functional connection between EGFR and endosomal trafficking in TNBC is mutant p53 found in the most aggressive forms of TNBC. Mutant p53 acquires oncogenic functions and binds p63 protein, a member of p53 family with tumor suppressor activities. In the absence of functional p63 there is an upregulation of endosomal recycling EGFR and integrin to the membrane with increased proinvasive abilities of cancer cells. Blocking endosomal trafficking combined with anti-EGFR treatments may result in better clinical outcomes in TNBC." @default.
• W2067832306 created "2016-06-24" @default.
• W2067832306 creator A5007314770 @default.
• W2067832306 creator A5011632607 @default.
• W2067832306 creator A5066232855 @default.
• W2067832306 creator A5080206270 @default.
• W2067832306 date "2013-11-01" @default.
• W2067832306 modified "2023-10-16" @default.
• W2067832306 title "P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency" @default.
• W2067832306 cites W1506672302 @default.
• W2067832306 cites W1861588860 @default.
• W2067832306 cites W1966343493 @default.
• W2067832306 cites W1967182910 @default.
• W2067832306 cites W1968075505 @default.
• W2067832306 cites W1969886304 @default.
• W2067832306 cites W1972933671 @default.
• W2067832306 cites W1973250026 @default.
• W2067832306 cites W1974423469 @default.
• W2067832306 cites W1977898869 @default.
• W2067832306 cites W1978760581 @default.
• W2067832306 cites W1982745818 @default.
• W2067832306 cites W1984045427 @default.
• W2067832306 cites W1987577112 @default.
• W2067832306 cites W1988055795 @default.
• W2067832306 cites W1988881529 @default.
• W2067832306 cites W1989663680 @default.
• W2067832306 cites W1994093097 @default.
• W2067832306 cites W1998469703 @default.
• W2067832306 cites W2003396164 @default.
• W2067832306 cites W2004413102 @default.
• W2067832306 cites W2010618491 @default.
• W2067832306 cites W2010807493 @default.
• W2067832306 cites W2011912935 @default.
• W2067832306 cites W2016498201 @default.
• W2067832306 cites W2019664231 @default.
• W2067832306 cites W2023188630 @default.
• W2067832306 cites W2023755204 @default.
• W2067832306 cites W2025977492 @default.
• W2067832306 cites W2026175788 @default.
• W2067832306 cites W2028496807 @default.
• W2067832306 cites W2028862921 @default.
• W2067832306 cites W2029949793 @default.
• W2067832306 cites W2032943026 @default.
• W2067832306 cites W2034882416 @default.
• W2067832306 cites W2036245489 @default.
• W2067832306 cites W2045279426 @default.
• W2067832306 cites W2046133662 @default.
• W2067832306 cites W2048440069 @default.
• W2067832306 cites W2051073516 @default.
• W2067832306 cites W2054188457 @default.
• W2067832306 cites W2057559260 @default.
• W2067832306 cites W2063358226 @default.
• W2067832306 cites W2070480410 @default.
• W2067832306 cites W2072466401 @default.
• W2067832306 cites W2073576377 @default.
• W2067832306 cites W2074325696 @default.
• W2067832306 cites W2076118024 @default.
• W2067832306 cites W2079672764 @default.
• W2067832306 cites W2079852484 @default.
• W2067832306 cites W2081223018 @default.
• W2067832306 cites W2086515708 @default.
• W2067832306 cites W2097255042 @default.
• W2067832306 cites W2098503539 @default.
• W2067832306 cites W2099987999 @default.
• W2067832306 cites W2100484302 @default.
• W2067832306 cites W2101657563 @default.
• W2067832306 cites W2109840033 @default.
• W2067832306 cites W2115860567 @default.
• W2067832306 cites W2118728607 @default.
• W2067832306 cites W2120944127 @default.
• W2067832306 cites W2123419890 @default.
• W2067832306 cites W2125094267 @default.
• W2067832306 cites W2125589729 @default.
• W2067832306 cites W2128963138 @default.
• W2067832306 cites W2129189579 @default.
• W2067832306 cites W2131994307 @default.
• W2067832306 cites W2134539328 @default.
• W2067832306 cites W2143633028 @default.
• W2067832306 cites W2143898087 @default.
• W2067832306 cites W2144963939 @default.
• W2067832306 cites W2145702083 @default.
• W2067832306 cites W2147354890 @default.
• W2067832306 cites W2147543538 @default.
• W2067832306 cites W2150144117 @default.
• W2067832306 cites W2150762830 @default.
• W2067832306 cites W2153769134 @default.
• W2067832306 cites W2154156417 @default.
• W2067832306 cites W2158752744 @default.
• W2067832306 cites W2160234594 @default.
• W2067832306 cites W2165340471 @default.
• W2067832306 cites W2170216427 @default.
• W2067832306 doi "https://doi.org/10.1016/j.critrevonc.2013.05.003" @default.
• W2067832306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23755891" @default.
• W2067832306 hasPublicationYear "2013" @default.
• W2067832306 type Work @default.
• W2067832306 sameAs 2067832306 @default.
• W2067832306 citedByCount "32" @default.
• W2067832306 countsByYear W20678323062013 @default.

• next